AMLX Amylyx Pharmaceuticals, Inc.
$28.07▼ -0.81%
Healthcare
Other
After hours
$28.09▲ +0.07%
Oct 28, 7:34 PM ET
Volume 1.06M
Avg Volume (10D) 1.28M
Key Metrics & Fundamentals
Market Cap
$3.52B
P/E Ratio
–
Div Yield
0.00%
52W Range
10.83 - 41.14
% vs 50 MA
-10.34%
% vs 200 MA
40.88%
RSI-14
47.7
MACD Histogram
+0.1600
Beta (1Y vs SPY)
0.94
Free Cash Flow
-$31.45M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$45.65M
COGS
–
Operating Exp
$45.69M
Operating Income
-$45.69M
EBIT
-$45.69M
Pretax Income
-$43.42M
Net Income
-$43.42M
EPS (Diluted)
-0.39
Price & Volume History
Loading chart…
Recent News
Can Corcept Therapeutics Stock Rally 40% After This Dip?
Trefis · Oct 26, 2026 3:11 AM ET
Amylyx Pharmaceuticals Insider Sold Shares Worth $830,904, According to a Recent SEC Filing
MT Newswires · Oct 7, 2026 4:14 PM ET
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
Business Wire · Oct 6, 2026 8:00 AM ET
3 High Growth Stocks To Own In October 2026
Simply Wall St. · Oct 4, 2026 1:07 PM ET
Amylyx Pharmaceuticals And 2 More Quality Growth Stocks
Simply Wall St. · Oct 4, 2026 3:09 AM ET
Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment
MarketBeat · Oct 3, 2026 3:02 AM ET
Our Pick Of The Best Growth Stocks In September 2026
Simply Wall St. · Sep 25, 2026 6:09 PM ET
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
Business Wire · Sep 23, 2026 9:00 AM ET
Tortugas Neuroscience Announces Appointment of Jim Frates to Board of Directors
Business Wire · Sep 9, 2026 8:00 AM ET
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
Business Wire · Sep 8, 2026 9:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See AMLX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.